Free Trial
NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

Mesoblast logo
$15.81 +0.64 (+4.22%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$15.78 -0.03 (-0.19%)
As of 08/22/2025 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mesoblast Stock (NASDAQ:MESO)

Key Stats

Today's Range
$15.14
$15.91
50-Day Range
$10.16
$16.98
52-Week Range
$6.00
$22.00
Volume
162,232 shs
Average Volume
151,117 shs
Market Capitalization
$2.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Mesoblast Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

MESO MarketRank™: 

Mesoblast scored higher than 42% of companies evaluated by MarketBeat, and ranked 681st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mesoblast has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mesoblast has only been the subject of 2 research reports in the past 90 days.

  • Read more about Mesoblast's stock forecast and price target.
  • Earnings Growth

    Earnings for Mesoblast are expected to grow in the coming year, from ($0.70) to ($0.32) per share.

  • Price to Book Value per Share Ratio

    Mesoblast has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mesoblast's valuation and earnings.
  • Percentage of Shares Shorted

    2.29% of the float of Mesoblast has been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 9.9.
  • Change versus previous month

    Short interest in Mesoblast has recently decreased by 12.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Mesoblast does not currently pay a dividend.

  • Dividend Growth

    Mesoblast does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.29% of the float of Mesoblast has been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 9.9.
  • Change versus previous month

    Short interest in Mesoblast has recently decreased by 12.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Mesoblast has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Mesoblast this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mesoblast insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.43% of the stock of Mesoblast is held by institutions.

  • Read more about Mesoblast's insider trading history.
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Stock News Headlines

Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Successful Commercial Launch of Ryoncil®
See More Headlines

MESO Stock Analysis - Frequently Asked Questions

Mesoblast's stock was trading at $19.80 at the start of the year. Since then, MESO shares have decreased by 20.2% and is now trading at $15.81.

Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The company earned $2.14 million during the quarter, compared to the consensus estimate of $2 million.
Read the conference call transcript
.

Shares of Mesoblast reverse split on Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Mesoblast's top institutional shareholders include Summit X LLC (0.16%), Group One Trading LLC, Marex Group plc and Lazari Capital Management Inc. (0.04%).

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
8/30/2023
Today
8/23/2025
Next Earnings (Estimated)
8/27/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
CIK
1345099
Employees
80
Year Founded
2004

Price Target and Rating

High Price Target
$24.00
Low Price Target
$12.00
Potential Upside/Downside
+13.9%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
0.96
Quick Ratio
0.63

Sales & Book Value

Annual Sales
$5.90 million
Price / Sales
343.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.21 per share
Price / Book
3.76

Miscellaneous

Outstanding Shares
128,000,000
Free Float
103,934,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
2.40

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MESO) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners